As an impetus to the weight loss industry a panel comprising European experts recommended Sanofi-Aventis's anti-obesity pill Acomplia be approved for sales in the European Union. This news was brought to light by the company itself.
The action of the pill Acomplia (rimonabant) is to block a pleasure centre and so fight obesity. People on the pill eat less because they feel less pleasure associated with eating.
Data from a trial involving more than 6,600 patients worldwide was used for the recommendation. The trial showed that patients taking Acomplia 20 mg per day lost 7.5 kg for a two-year period. It also improved waist circumference, HbA1c, HDL cholesterol and blood fat.
The European Union will make its decision within two to three months to decide whether Acomplia can be sold in Europe.
Sanofi says in its news release, "Following European marketing authorization, Acomplia will be available in European Union countries for prescription as a 20mg tablet to be taken once daily. First launches are anticipated during the second half of 2006."
So European markets would hopefully soon find this pill sold to public.